Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPA-2: Alfimeprase in Acute PAO
NCT00115999Phase 3Completed
- Sponsor
- Oruka Therapeutics
- Start
- Apr 2005
- Primary completion
- Feb 2007
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alfimeprase in acute peripheral arterial occlusion (APAO) (3 arms), sponsored by Oruka Therapeutics. Primary endpoint: Open Vascular Surgery Free Rate at 30 days. Started Apr 2005; status: completed.
02
Drugs
alfimeprase
03
Conditions
acute peripheral arterial occlusion (APAO)
Beyond the preview
Go deeper on NCT00115999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115999.